Medical - Devices
Compare Stocks
5 / 10Stock Comparison
SNWV vs MLSS vs XTNT vs LNTH vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Drug Manufacturers - Specialty & Generic
Medical - Instruments & Supplies
SNWV vs MLSS vs XTNT vs LNTH vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies |
| Market Cap | $143M | $37M | $80M | $5.92B | $1.92B |
| Revenue (TTM) | $41M | $9M | $133M | $1.55B | $674M |
| Net Income (TTM) | $-7M | $-7M | $2M | $279M | $-173M |
| Gross Margin | 77.7% | 72.8% | 62.0% | 60.5% | 75.2% |
| Operating Margin | 16.6% | -77.0% | 4.8% | 18.8% | -27.2% |
| Forward P/E | 17.4x | — | — | 17.5x | — |
| Total Debt | $25M | $349K | $35M | $738K | $290M |
| Cash & Equiv. | $10M | $3M | $6M | $359M | $103M |
SNWV vs MLSS vs XTNT vs LNTH vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SANUWAVE Health, In… (SNWV) | 100 | 16.1 | -83.9% |
| Milestone Scientifi… (MLSS) | 100 | 25.5 | -74.5% |
| Xtant Medical Holdi… (XTNT) | 100 | 46.3 | -53.7% |
| Lantheus Holdings, … (LNTH) | 100 | 662.8 | +562.8% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SNWV vs MLSS vs XTNT vs LNTH vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SNWV is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 60.0%, EPS growth 42.3%, 3Y rev CAGR 35.9%
- 60.0% revenue growth vs MLSS's -12.2%
- Better valuation composite
MLSS plays a supporting role in this comparison — it may shine differently against other peers.
XTNT lags the leaders in this set but could rank higher in a more targeted comparison.
LNTH carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 0.47
- 41.9% 10Y total return vs SNWV's -20.7%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
- Beta 0.47, current ratio 2.70x
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 60.0% revenue growth vs MLSS's -12.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 18.0% margin vs MLSS's -76.8% | |
| Stability / Safety | Beta 0.47 vs NVCR's 2.20, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +13.1% vs MLSS's -48.5% | |
| Efficiency (ROA) | 12.4% ROA vs MLSS's -86.6%, ROIC 30.6% vs -121.3% |
SNWV vs MLSS vs XTNT vs LNTH vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SNWV vs MLSS vs XTNT vs LNTH vs NVCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LNTH leads in 4 of 6 categories
SNWV leads 0 • MLSS leads 0 • XTNT leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LNTH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LNTH is the larger business by revenue, generating $1.5B annually — 170.2x MLSS's $9M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to MLSS's -76.8%. On growth, MLSS holds the edge at +25.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $41M | $9M | $133M | $1.5B | $674M |
| EBITDAEarnings before interest/tax | $8M | -$7M | $11M | $347M | -$165M |
| Net IncomeAfter-tax profit | -$7M | -$7M | $2M | $279M | -$173M |
| Free Cash FlowCash after capex | -$784,000 | -$5M | $5M | $372M | -$48M |
| Gross MarginGross profit ÷ Revenue | +77.7% | +72.8% | +62.0% | +60.5% | +75.2% |
| Operating MarginEBIT ÷ Revenue | +16.6% | -77.0% | +4.8% | +18.8% | -27.2% |
| Net MarginNet income ÷ Revenue | -17.1% | -76.8% | +1.3% | +18.0% | -25.7% |
| FCF MarginFCF ÷ Revenue | -1.9% | -57.9% | +3.9% | +24.0% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.3% | +25.3% | +19.0% | +1.2% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +117.4% | — | +123.7% | +76.5% | -100.0% |
Valuation Metrics
Evenly matched — XTNT and LNTH each lead in 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, LNTH's 14.6x EV/EBITDA is more attractive than SNWV's 24.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $143M | $37M | $80M | $5.9B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $158M | $34M | $109M | $5.6B | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.37x | -7.94x | -4.75x | 26.69x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.43x | — | — | 17.52x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 24.09x | — | — | 14.61x | — |
| Price / SalesMarket cap ÷ Revenue | 4.38x | 4.27x | 0.68x | 3.84x | 2.92x |
| Price / BookPrice ÷ Book value/share | — | 6.42x | 1.77x | 5.72x | 5.51x |
| Price / FCFMarket cap ÷ FCF | 72.67x | — | — | 16.73x | — |
Profitability & Efficiency
LNTH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-2 for MLSS. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), SNWV scores 7/9 vs XTNT's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -2.1% | +3.8% | +24.3% | -50.8% |
| ROA (TTM)Return on assets | -21.7% | -86.6% | +1.8% | +12.4% | -16.5% |
| ROICReturn on invested capital | +159.8% | -121.3% | -12.8% | +30.6% | -16.4% |
| ROCEReturn on capital employed | — | -94.2% | -17.9% | +17.1% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 | 2 | 5 | 5 |
| Debt / EquityFinancial leverage | — | 0.06x | 0.82x | 0.00x | 0.85x |
| Net DebtTotal debt minus cash | $15M | -$3M | $29M | -$358M | $187M |
| Cash & Equiv.Liquid assets | $10M | $3M | $6M | $359M | $103M |
| Total DebtShort + long-term debt | $25M | $349,054 | $35M | $738,000 | $290M |
| Interest CoverageEBIT ÷ Interest expense | 0.13x | — | 1.55x | 11.72x | -96.80x |
Total Returns (Dividends Reinvested)
LNTH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, LNTH leads with a +13.1% total return vs MLSS's -48.5%. The 3-year compound annual growth rate (CAGR) favors SNWV at 28.8% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -42.4% | +61.7% | -24.0% | +35.3% | +28.3% |
| 1-Year ReturnPast 12 months | -47.4% | -48.5% | +10.0% | +13.1% | +1.1% |
| 3-Year ReturnCumulative with dividends | +113.5% | -37.5% | -12.3% | -4.0% | -75.7% |
| 5-Year ReturnCumulative with dividends | -72.2% | -80.9% | -66.1% | +314.2% | -91.3% |
| 10-Year ReturnCumulative with dividends | -20.7% | -79.9% | -97.8% | +4192.5% | +30.3% |
| CAGR (3Y)Annualised 3-year return | +28.8% | -14.5% | -4.3% | -1.4% | -37.6% |
Risk & Volatility
LNTH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs SNWV's 35.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 0.94x | 0.69x | 0.47x | 2.20x |
| 52-Week HighHighest price in past year | $46.59 | $1.05 | $0.95 | $93.00 | $20.06 |
| 52-Week LowLowest price in past year | $15.36 | $0.22 | $0.44 | $47.25 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +35.7% | +44.7% | +60.0% | +97.8% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 34.2 | 72.6 | 60.9 | 61.2 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 84K | 2.3M | 142K | 886K | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SNWV as "Buy", LNTH as "Buy", NVCR as "Buy". Consensus price targets imply 224.3% upside for SNWV (target: $54) vs 11.0% for LNTH (target: $101).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | $54.00 | — | — | $101.00 | $33.50 |
| # AnalystsCovering analysts | 2 | — | — | 17 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +5.1% | 0.0% |
LNTH leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
SNWV vs MLSS vs XTNT vs LNTH vs NVCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SNWV or MLSS or XTNT or LNTH or NVCR a better buy right now?
For growth investors, SANUWAVE Health, Inc.
(SNWV) is the stronger pick with 60. 0% revenue growth year-over-year, versus -12. 2% for Milestone Scientific Inc. (MLSS). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate SANUWAVE Health, Inc. (SNWV) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SNWV or MLSS or XTNT or LNTH or NVCR?
On forward P/E, SANUWAVE Health, Inc.
is actually cheaper at 17. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SNWV or MLSS or XTNT or LNTH or NVCR?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SNWV or MLSS or XTNT or LNTH or NVCR?
By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.
(LNTH) is the lower-risk stock at 0. 47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 370% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — SNWV or MLSS or XTNT or LNTH or NVCR?
By revenue growth (latest reported year), SANUWAVE Health, Inc.
(SNWV) is pulling ahead at 60. 0% versus -12. 2% for Milestone Scientific Inc. (MLSS). On earnings-per-share growth, the picture is similar: SANUWAVE Health, Inc. grew EPS 42. 3% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, SNWV leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SNWV or MLSS or XTNT or LNTH or NVCR?
Lantheus Holdings, Inc.
(LNTH) is the more profitable company, earning 15. 2% net margin versus -96. 1% for SANUWAVE Health, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -78. 3% for MLSS. At the gross margin level — before operating expenses — SNWV leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SNWV or MLSS or XTNT or LNTH or NVCR more undervalued right now?
On forward earnings alone, SANUWAVE Health, Inc.
(SNWV) trades at 17. 4x forward P/E versus 17. 5x for Lantheus Holdings, Inc. — 0. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNWV: 224. 3% to $54. 00.
08Which pays a better dividend — SNWV or MLSS or XTNT or LNTH or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SNWV or MLSS or XTNT or LNTH or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Lantheus Holdings, Inc.
(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNTH: +41. 9%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SNWV and MLSS and XTNT and LNTH and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SNWV is a small-cap high-growth stock; MLSS is a small-cap quality compounder stock; XTNT is a small-cap high-growth stock; LNTH is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.